December 28, 2023 | Daily JAM, Jubak Picks, Mid Term, Morning Briefing, Special Reports, Top 50 Stocks, Volatility |
GREATER Growth Stock Pick #8: BYD (BYDDF). I know; I know. What’s a Chinese stock doing on this list? It’s here because BYD, not Tesla (TSLA) is the big growth story in electric vehicles and not just for this month–but for years. And because I can see two catalysts that are about to power this stock higher. Morningstar calculates that BYD is 20% undervalued right now. Because this is a China stock we’ll need to take a deep look at valuation later in this post. But first, the growth story.
December 15, 2023 | COST, Daily JAM, Jubak Picks |
Costco Wholesale (COST) reported earnings for its fiscal first quarter of 2024 and declared a long anticipated special dividend of $15 a share. The stock closed up 4.61% on Friday, December 15.
December 11, 2023 | Daily JAM, DHR, Jubak Picks, Special Reports |
GREATER Growth Stock Pick #6: Danaher (DHR). Danaher is a smart (that’s key) serial acquirer–and asset divester–in the life sciences space. And that makes this stock very interesting in an environment where small, young life sciences companies might be looking for help/rescue/acquisition because they can’t raise capital in a tough part of the credit cycle. I like Danaher now, as well, because the stock looks to have just about completed its re-rating after a spike in sales during the Covid pandemic led to over enthusiasm about the stock.
November 29, 2023 | Daily JAM, GM, Jubak Picks, Stock Alerts |
Shares of General Motors (GM) are up 11.39% today, November 29, on news that the company will boost its dividend by 33% (to 12 cents a share from 9 cents) and repurchase $10 billion of shares. I’m selling my position in the stock in my 12-18 month Jubak Picks Portfolio. That position is now down 10.03% since I added it to the portfolio on October 4, 2022. I don’t see anything in this report that changes the fundamentals of GM’s car business. Yes, the company demonstrates today with its biggest-ever buyback plan that its legacy gas-powered vehicle business throws off tremendous amounts of cash. Now. But the company has pulled back on many of the expensive investments that would have brought GM into the electric vehicle future.
November 3, 2023 | Daily JAM, Jubak Picks, RWM, Short Term |
On Monday, I will add to my short position in the small-cap Russell 2000 by buying more of the ProShares Short Russell 2000 ETF (RWM) for my Jubak Picks Portfolio. This buy will give me two positions in the ProShares Short Russell ETF. The first position, added to the portfolio on July 23, 2023 is up 0.08% as of the close on November 3. Why go all in on shorting the Russell now?
November 2, 2023 | Daily JAM, GOLD, Stock Alerts |
Yesterday, Thursday, November 2, Barrick Gold (GOLD) reported earnings of 24 cents a share for the company’s this quarter. That was ahead of the 21 cents a share consensus estimate among Wall Street analysts. In the third quarter of quarter of 2022, the company reported earnings of 13 cents a share. The surprise was the fourth for Barrack in the last four quarters. But to me other news overshadowed the earnings themselves.
October 30, 2023 | BHP, CAT, Daily JAM, DE, Dividend Income, Jubak Picks, Special Reports, Top 50 Stocks |
Today I posted Step #8 in my Special Report: 8 Steps to Protect Your Portfolio from the Global Debt Bomb. I recommended selling Deere (DE), Caterpillar (CAT), and BHP Group (BHP) out of portfolios ahead of rising yields i the bond market. (In the case of Deere, I said I would keep my position in my long-term portfolio but sell the position in my 12-18 month portfolio.) Here’s what I posted in my Special Report
October 30, 2023 | Daily JAM, F, GM, Jubak Picks, Special Reports |
I added Step #7 to my Special report: 8 Steps to Protect Your Portfolio from the Global Debt Bomb today. And my advice is to sell Ford and General Motors sometime between now and before the December 13 meeting of the Federal Reserve. Here’s what I wrote in that Special Report.
October 24, 2023 | AAPL, ALB, CAT, Daily JAM, DE, Dividend Income, DUK, F, GM, Jubak Picks, Mid Term, NI, SCCO, Short Term, Special Reports, Top 50 Stocks |
I’ve hi-lighted the key characteristics of the coming global debt bomb explosion that investors MUST include in any plan to protect a portfolio from the explosion of this bomb.
October 10, 2023 | Daily JAM, Dividend Income, Jubak Picks, PEP |
Clearly, inflation isn’t bad for everyone. Not if you have pricing power, anyway. Today, PepsiCo (PEP) reported earnings and sales that a beat Wall Street estimates, and raised its guidance for the next quarter.
October 6, 2023 | Daily JAM, Dividend Income, Jubak Picks |
The Wall Street Journal has reported that Exxon Mobil (XOM) is in advanced talks to buy Pioneer Natural Resources (PXD) in a deal valued at $60 billion. Pioneer currently has a market cap of $55 billion. Through in th debt that Exxon would be buying and there’s not a lot of extra upside here, in my opinion. Today’s 10.45% jump in pioneer shares to care of a lot of any potential deal premium. (I’m assuming that the report is accurate. Today’s news story follows on earlier speculation that the two companies were talking.) Unless you think another bidder will emerge–difficult but not impossible at this deal size, I’d sell my shares here. I like Pioneer as an independent big dividend paye
September 14, 2023 | Daily JAM, Jubak Picks, MRNA |
Shares of Moderna (MRNA) closed up 3.18% yesterday, September 13, on news that
1. The Food & Drug Administration has approved updated Covid-19 vaccine boosters (including one from Moderna) and that the Centers for Disease Control was recommending the boosters for adults and children older than 6 months. 2. The company announced that the newest results from Phase 3 clinical trials for an updated version of its flu vaccine, mRNA-1010, had met all primary endpoints in a Phase 3 trial, Compared to Glaxo’s Fluarix, Moderna’s vaccine showed higher antibody levels for all four influenza strains (two each for influenza A and B) recommended by the World Health Organization (WHO) as well as higher seroconversion rates. This comes after an earlier version of the vaccine failed to demonstrate superiority for the B strains. The company expects to meet with regulators very soon and, depending on guidance received, the flu shot could launch as soon as next year, CEO Stephane Bancel told Fierce Biotech. “We’ll know more in a few months when we speak to regulators, but [we’re] trying to go as fast as we can,” he said. Of these two pieces of news I’d say No 2 is way, way more important
